Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly

Cardiovascular Drugs and Therapy

Volumn 29, Issue 2, 2015, Pages 187-197

  Lin, Liang ^a   Teng, Monica ^a   Zhao, Ying Jiao ^a   Khoo, Ai Leng ^a   Seet, Raymond Chee Seong ^b   Yong, Quek Wei ^c   Yeo, Tiong Cheng ^d   Lim, Boon Peng ^a  

^a NATIONAL HEALTHCARE GROUP   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^c TAN TOCK SENG HOSPITAL   (Singapore)

^d NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Cardiovascular disease; Cost effectiveness; Elderly; Primary prevention; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH CARE SYSTEM; HEART INFARCTION; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SINGAPORE; TREATMENT OUTCOME; AGE; COST BENEFIT ANALYSIS; ECONOMIC MODEL; ECONOMICS; HEALTH CARE COST; MYOCARDIAL INFARCTION; SEXUAL DEVELOPMENT; STATISTICS AND NUMERICAL DATA; STROKE; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MODELS, ECONOMIC; MYOCARDIAL INFARCTION; PRIMARY PREVENTION; QUALITY-ADJUSTED LIFE YEARS; SEX CHARACTERISTICS; SINGAPORE; STROKE;

EID: 84928947220     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-015-6584-7     Document Type: Article

References (40)

1. Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746–53.
2. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.
3. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. 2011; CD004816.
4. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ (Clin Res ed). 2009;338:b2376.
5. Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90.
6. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/american heart association task force on practice guidelines. J Am Coll Cardiol. 2014;63:2889–934.
7. Ioannidis JA. More than a billion people taking statins? Potential implications of the new cardiovascular guidelines. JAMA: J Am Med Assoc. 2014;311:463–4.
8. Lazar LD, Pletcher MJ, Coxson PG, et al. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 2011;124:146–53.
9. Greving JP, Visseren FL, de Wit GA, et al. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ (Clin Res ed). 2011;342:d1672.
10. Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11:178.
11. The State of Aging and Health in America 2013. In: Centers for Disease Control and Prevention UDoHaHS, ed. Atlanta, GA, 2013.
12. Health at a Glance 2013. OECD Indicators. OECD Publishing, 2013.
13. Department of Statistics, Singapore. Complete life tables 2008–2013 for Singapore Resident Population. Available at: http://www.singstat.gov.sg/publications/publications_and_papers/births_and_deaths/lifetable08-13.pdf. Last accessed 1 December 2014.
14. Office for National Statistics, United Kingdom. National life tables 2011–2013. Available at: http://www.ons.gov.uk/ons/taxonomy/index.html?nscl=Life+Tables#tab-data-tables. Last accessed 1 December 2014.
15. Arias E. United States life tables, 2010, National vital statistics reports, vol. 7. 63rd ed. Hyattsville: National Center for Health Statistics; 2014.
16. Brønnum-Hansen H, Davidsen M, Thorvaldsen P, et al. Long-term survival and causes of death after stroke. Stroke. 2001;32(9):2131–6. September 1, 2001.
17. Smolina K, Wright FL, Rayner M, et al. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ: Cardiovasc Qual Outcomes. 2012;5(4):532–40. July 1, 2012.
18. Ellis JJ, Erickson SR, Stevenson JG, et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004;19(6):638–45.
19. Bhardwaj S, Selvarajah S, Schneider EB. Muscular effects of statins in the elderly female: a review. Clin Interv Aging. 2013;8:47–59.
20. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97:52C–60C.
21. Luengo-Fernandez R, Gray AM, Bull L, et al. Quality of life after TIA and stroke: ten-year results of the Oxford vascular study. Neurology. 2013;81:1588–95.
22. Xie J, Wu EQ, Zheng Z-J, et al. Patient-reported health status in coronary heart disease in the United States: age, sex, racial, and ethnic differences. Circulation. 2008;118:491–7.
23. Pignone M, Earnshaw S, Tice JA, et al. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006;144:326–36.
24. Pletcher MJ, Lazar L, Bibbins-Domingo K, et al. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009;150:243–54.
25. Schreiber DH, Anderson TR. Statin-induced rhabdomyolysis. J Emerg Med. 2006;31:177–80.
26. Skrabal MZ, Stading JA, Cannella CA, et al. Two cases of rhabdomyolysis associated with high-dose simvastatin. Am J Health Syst Pharm: AJHP: Off J Am Soc Health Syst Pharm. 2003;60:578–81.
27. Tan WS, Heng BH, Chua KS, et al. Factors predicting inpatient rehabilitation length of stay of acute stroke patients in Singapore. Arch Phys Med Rehabil. 2009;90:1202–7.
28. Department of Statistics, Singapore. Latest data on GDP per capita. Available at: http://www.singstat.gov.sg/statistics/latest_data.html#1. Last accessed 1 September 2014.
29. Sachs JD. Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commision on Macroeconomics and Health. Geneva, Switzerland: World Health Organisation, 2011. Available at: http://whqlibdoc.who.int/publications/2001/924154550x.pdf. Accessed on 1 September 2014.
30. Kostis WJ, Cheng JQ, Dobrzynski JM, et al. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol. 2012;59:572–82.
31. Bushnell CD, Reeves MJ, Zhao X, et al. Sex differences in quality of life after ischemic stroke. Neurology. 2014;82:922–31.
32. Alexander KP, Newby LK, Armstrong PW, et al. Acute coronary care in the elderly, part II: ST-segment–elevation myocardial infarction: a scientific statement for healthcare professionals from the American heart association council on clinical cardiology: in collaboration with the society of geriatric cardiology. Circulation. 2007;115:2570–89.
33. Mehta RH, Rathore SS, Radford MJ, et al. Acute myocardial infarction in the elderly: differences by age. J Am Coll Cardiol. 2001;38:736–41.
34. Collier DJ, Poulter NR, Dahlof B, et al. Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian cardiac outcomes trial lipid-lowering arm. J Hypertens. 2011;29:592–9.
35. Bruckert E, Lievre M, Giral P, et al. Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients. Am J Geriatr Cardiol. 2003;12:225–31.
36. Neil HA, DeMicco DA, Luo D, et al. Analysis of efficacy and safety in patients aged 65–75 years at randomization: collaborative atorvastatin diabetes study (CARDS). Diabetes Care. 2006;29:2378–84.
37. Collins R, Armitage J, Parish S, et al. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–16.
38. Glynn RJ, Koenig W, Nordestgaard BG, et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med. 2010;152:488–96. W174.
39. Nakaya N, Mizuno K, Ohashi Y, et al. Low-dose pravastatin and age-related differences in risk factors for cardiovascular disease in hypercholesterolaemic Japanese: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study). Drugs Aging. 2011;28:681–92.
40. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30.